Biohaven’s Nurtec brings in $10M in revenue
A newly approved migraine drug from Biohaven Pharmaceuticals brought in nearly $10 million for the company during the first full quarter since its launch. CEO...
Home >
Access the latest news, business developments, company updates, industry trends, events and more.
A newly approved migraine drug from Biohaven Pharmaceuticals brought in nearly $10 million for the company during the first full quarter since its launch. CEO...
Bristol Myers Squibb will train hundreds of racially and ethnically diverse clinical investigators and set up trial sites in under-served communities as a part of a...
Alexion Pharmaceuticals has appointed Uzair Qadeer as the company’s first Chief Diversity Officer. In this new role, Mr. Qadeer will be responsible for shaping the...
Tangen Biosciences, a molecular diagnostic company located in Branford, CT has closed a $12.2 million Series B Preferred Stock financing with participation of current and new...
A team at UConn is part of an international consortium of scientists taking the next step toward the end of congenital disease. Benton Graveley, a...
The EIA is back! Now’s the time to start your application for Connecticut’s longest-running pitch competition, CTNext’s Entrepreneur Innovation Awards. The event features startup and...
BIO has announced the BIOEquality Agenda, which aims to attack the systemic inequality, injustice, and unfair treatment of women and communities of color through the...
Systemic lupus erythematosus (SLE), the most common type of lupus, is an autoimmune disease that affects a variety of tissues, including joints, skin, brain and...
Alexion Pharmaceuticals reports that the European Commission has approved ULTOMIRIS® (ravulizumab) for the treatment of adults and children with a body weight of 10 kg or...
New Haven’s Biohaven Pharmaceuticals has enrolled the first patients in a first-of-its kind clinical trial led by Massachusetts General Hospital for patients with amyotrophic lateral...